Insulet PODD
Insulet Q2 FY25: revenue $649.1M, up 33%; diluted EPS $0.32
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001145197-25-000038
Key figures from this report
These are the numbers Insulet reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$649.1M+33% from $488.5M in Q2 FY2410-Q income statement, on EDGAR
- Net income$22.5M−88% from $188.6M in Q2 FY2410-Q income statement, on EDGAR
- Diluted EPS$0.32−88% from $2.59 in Q2 FY2410-Q income statement, on EDGAR
- Cash and cash equivalents$1.1B+37% from $821.0M in Q2 FY2410-Q balance sheet, on EDGAR
- Cash from operations$196.5M+104% from $96.5M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- MiniMed Group MMED
- STERIS STE public float $24.2B, Sep 30, 2025
- Zimmer Biomet Holdings ZBH public float $18.0B, Jun 30, 2025
- Baxter International BAX public float $16.0B, Jun 30, 2025
- West Pharmaceutical Services WST public float $15.7B, Jun 30, 2025
